Syngap families can join the registry here.

SYNGAP1 - Data Collection Program

SYNGAP1 patients, families, and communities are excited to participate in data collection to expand and improve medical research. By coming to this site, you can begin the first step in making your patient information available to researchers. By generating the most comprehensive SYNGAP1 Data Collection Program, we can accelerate research and the development of new drugs, devices, or other therapies. Only you hold the key to unlock future discoveries.

Why Should You Participate?

The surveys you will take in the SYNGAP1 Data Collection Program are critical to the drug and treatment development process. Our goal is to make the process as easy as possible for you. The SYNGAP1 Data Collection Program uses a collaborative technology platform powered by RARE-X. RARE-X is a nonprofit created to accelerate rare disease research, treatments, and cures by removing barriers for data collection and sharing. By participating, you are…

  • Informing researchers how a disease or condition changes over time
  • Enabling better data to use in clinical trials
  • Reducing the time it takes to study new medicines in clinical trials
  • Speeding up the time to get therapeutics to patients
  • Enabling the use of data as a placebo (instead of actual patients) in a clinical trial

How it Works:

  • No clinic visits required, and there is no cost to you
  • Patients and Caregivers retain full control over who has access to  patients’ health information
  • With your consent, clinicians (doctors), researchers, and drug development companies (biopharma) can access de-identified data to aid research
  • Enrolling in the SYNGAP1 Data Collection Program requires minimal time, and you can come back to the site at your convenience to update your information

Become a SYNGAP1 data sharer to help advance research and accelerate treatments. Please join us.

You may also like

57 - Discussing SYNGAP1 Related Developmental Disorders

Holly Harris, MD

Baylor College of Medicine

59 - Finding more SYNGAP1 patients with Probably Genetic

Lukas Lange, CEO

Probably Genetic

56 - Six Steps to Connecting the Dots: An Objective Approach for Meaningful Parent Participation in the Education of Children with Disabilities Under the IDEA

Richard Peterson, JD, MDR, LLM